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eWe are grateful for having the opportunity to reply to the letter
from Stephen McKenna and John Brodersen [1], in which the au-
thors discuss several issues related to our work. Our study was
intended to pursue thework begun by others to provide normative
data on the quality of life assessment of growth hormone defi-
ciency in adults (QoL-AGHDA) questionnaire to help interpret QoL-
AGHDA data collected in growth hormone deficient (GHD) pa-
tients. In this context, we aimed to complete previous studies
that enabled reference values for the QoL-AGHDA question-
naire to be collected in general populations in European coun-
tries [2–6]. Therefore, we would like to provide some clarification
as it seems that the objective of our work has not been fully un-
derstood by the authors of the letter to editor.
The QoL-AGHDA questionnaire was developed according to
the needs-based approach of QoL, and is indeed intended to be
used in GHD patients and not in healthy individuals. Thus, the
questionnaire was psychometrically validated in GHD patients in
theUK, Sweden, Germany, Italy, and Spain [7]. The translation and
psychometric validation of the French version of the QoL-AGHDA
questionnaire in GHD patients was undertaken and published by
Leplège et al. [8] in 2003. In 2000, Wiren et al. [6] published a work
aiming to validate the QoL-AGHDAquestionnaire in Sweden using
Rasch analysis and to compare the QoL of GHD patients to that of
a random sample of the Swedish population [6]. Reference values
were collected in other European countries [2–5], butwithoutmea-
suring the scaling properties of the QoL-AGHDA questionnaire in
general populations. Themain purpose of our study was to collect
reference QoL-AGHDA data for the French general population. To
ensure scientifically sound results to be produced, we also as-
sessed the psychometric properties of the French QoL-AGHDA
questionnaire in our study sample.
Contrary to the study conducted by Wiren et al. [6], our study
was not designed to directly compare a patient sample to a ran-
dom sample of the general population using Rasch analysis. In
order to focus our article on the main objective (that was to pro-
vide additional reference values for the QoL-AGHDA question-
naire), we deliberately did not develop on technical aspects of the
Rasch analysis in the article. Nevertheless, in order to clarify some
doubts from the authors of the letter, we would like to state that
the overall fit of our Rasch model was good (item-trait interaction
p [2] 1000; separation index 0.88).We appreciate that it would
ave been interesting to explore the issue of differential item func-
ioning (DIF) between males and females as regards the results
bserved on themeanQoL-AGHDA total score. The objective of the
tudy, however, was to establish reference values on the observed
core to make easy comparison with GHD patients. Correcting the
core by gender for DIF would have prevented this simple and
irect comparison, which, for example, may be conducted by cli-
icians to compare with QoL of their patients.One major concern when using QoL instruments is the inter-
retation of data collected with suchmeasures, and reference val-
es represent a simple and direct way for clinicians to convert a
oL score given by a patient into interpretable and worthwhile
nformation. Such reference data have been collected for many
ears, for both generic and specific questionnaires, including the
oL-AGHDA questionnaire [9–12]. In particular, Wiren [6] com-
aredQoL-AGHDAdata betweenGHDpatients and a randomsam-
le of the Swedish population, with no reference to the potential
rrelevance of using such a population as comparator.We are thus
urprised by the statementmade by the authors of the letter about
he irrelevance of comparison with healthy individuals, as Ste-
hen Mc Kenna contributed to the Swedish study.
As explained in the article, the issue of which population
hould be used to compare QoL-AGHDA data in GHD patients re-
ains an open question. Both general and other disease popula-
ions present advantages and disadvantages, and it seems obvious
hat the comparator should be chosen depending on the research
uestion to be addressed [13,14]. In the context of choosing the
ppropriate comparator, it is important to collect as much infor-
ation as possible to enable a comparison that is as accurate and
elevant as possible to be conducted. Our study falls within this
ramework as we chose to collect reference values in the French
eneral population to complete previous studies. Moreover, refer-
nce values collected in general populations have a major addi-
ional interest compared to reference values collected in disease
opulations: theymay enable utility values to be derived for use in
conomic evaluation [15].
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ERRATUM
In Value in Health, Volume 14, Issue 1, the article, ”Exact Method for Computing Absolute Percent Change in a Dichotomous Outcome
from Meta-Analytic Effect Size: Improving Impact and Cost-Outcome Estimates,” denotes that Delia Hendrie is with the School of
Population Health, University of Western Australia, Perth, Australia. Her correct affiliation is Curtin Health Innovation Research
Institute (CHIRI), Population Health Research, Curtin University, Perth, Western Australia.
ERRATUM
InValue in Health, Volume 13, Issue 8, the article, “Use of aDisease-Specific Instrument in Economic Evaluations:MappingWOMAConto the
EQ-5D Utility Index,” Table 1 was published with some incorrect numbers. This table has been corrected and is available here.
Table 1 – Demographic characteristics and quality of life
scores for the study samples.
Total sample (n257)
Demographic characteristics
Age, mean (SD) 66.5 (7.6)
Female, N (%) 213 (82.9)
Ethnicity, N (%)
Chinese 230 (89.5)
Malay 10 (3.9)
Indian 14 (5.4)
Others 3 (1.2)
Formal education, N (%)
1 year 107 (41.6)
1-6 years 85 (33.1)
7-10 years 46 (17.9)
10 years 14 (5.4)
Married, N (%) 235 (91.4)
Retirees/homemaker, N (%) 222 (86.4)
BMI, mean (SD) 28.2 (4.7)
Years with OA, mean (SD) 6 (5.2)
EQ-5D scores, mean (SD) 0.62 (0.13)
WOMAC scores, mean (SD)
Pain 6.64 (3.38)
Stiffness 3.12 (2.02)
Function 26.24 (10.18)
BMI, body mass index; SD, standard deviation; OA, osteoarthritis;
WOMAC, Western Ontario and McMaster Universities Osteoarthritis
